PS
CRNX icon

Principal Securities’s Crinetics Pharmaceuticals CRNX Stock Holding History

Principal Securities’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80
Closed -$3.33K – 1780
2025
Q3 		$3.33K Hold
80
– – ﹤0.01% 3089
2025
Q2 		$2.3K Buy
80
+3
+4% +$93 ﹤0.01% 3100
2025
Q1 		$3.94K Hold
77
– – ﹤0.01% 2854
2024
Q4 		$3.94K Buy
77
+11
+17% +$615 ﹤0.01% 2851
2024
Q3 		$3.37K Buy
66
+21
+47% +$1.08K ﹤0.01% 2804
2024
Q2 		$2.02K Buy
45
+17
+61% +$785 ﹤0.01% 2910
2024
Q1 		$1.31K Buy
+28
New +$1.1K ﹤0.01% 2979

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Principal Securities's CRNX Position: Q4 2025 in Review

Principal Securities sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 80 shares — an estimated $3.33K sold.

Principal Securities first reported a position in CRNX in Q1 2024 and held it in 7 quarters. The position peaked at $3.94K in Q1 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Principal Securities reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 80 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $3.33K.
  • Principal Securities first reported a position in Crinetics Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Principal Securities's Crinetics Pharmaceuticals position peaked at $3.94K in Q1 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.